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Abstract Although it has been shown that osteocalcin
functions as a hormone in the regulation of glucose
metabolism and fat mass, no population-based study to date
has addressed serum osteocalcin levels in relation to energy
metabolism concurrent with bone metabolism in post-
menopausal women. In a population-based study, cardio-
vascular risk factors, high-sensitivity C-reactive protein
(hs-CRP), osteoprotegerin, receptor activator of nuclear
factor-jB ligand, osteocalcin, CrossLaps, alkaline phos-
phatase, and bone mineral density (BMD) at the lumbar
spine (L2–L4) and the proximal femur were measured in
382 Iranian postmenopausal women. In multiple logistic
regression analysis, lower osteocalcin and CrossLaps levels
were associated with a higher odds ratio (OR) of having
type 2 diabetes mellitus when adjustments were made for
age, hs-CRP, cardiovascular risk factors, BMD, and
markers of bone metabolism [OR 5.17, CI (2.66–10.04),
p \ 0.0001 and OR 2.51, CI (1.37–4.61), p = 0.003,
respectively]. However, lower alkaline phosphatase levels
were associated with a lower OR of having type 2 diabetes
mellitus [OR 0.28, CI (0.15–0.52), p \ 0.0001] in regres-
sion analysis. No significant difference was found between
serum osteocalcin levels of those with and without meta-
bolic syndrome. Among the metabolic syndrome compo-
nents, low osteocalcin levels had significant associations
with elevated blood glucose [OR 1.89, CI (1.16–3.07),
p = 0.010] and elevated waist circumference [OR 2.53, CI
(1.13–5.67), p = 0.024] in multivariate analyses. In con-
clusion, serum osteocalcin was independently associated
with glucose intolerance and abdominal obesity as the
components of metabolic syndrome and type 2 diabetes
mellitus in postmenopausal women. Since CrossLaps and
alkaline phosphatase levels were independently associated
with the presence of type 2 diabetes mellitus, the unique
contribution of osteocalcin in glucose metabolism could
not be concluded.
Keywords Osteocalcin  Diabetes mellitus  Metabolic
syndrome  Postmenopausal women
Introduction
In recent years, a growing body of scientific and clinical
evidence has indicated that we have encountered a para-
digm of integrative physiology in bone and energy
homeostasis [1, 2]. One of the osteoblast-specific proteins,
osteocalcin, is encoded by the bone c-carboxyglutamate
(Gla) protein BGLAP and is secreted in the general cir-
culatory system during osteogenesis [3]. The revolutionary
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finding that osteocalcin positively regulates energy
metabolism through increased fat metabolism, energy
expenditure, the insulin secretion capacity of the pancreas,
and release of adiponectin from adipocytes, in addition to
inducing mitochondrial proliferation and function in
genetically modified mice [1], confirmed that a complex
crosstalk between bones and adipocytes in energy metab-
olism may be present [2].
Although these animal-based studies are certainly of
interest, the clinical relevance of osteocalcin has seldom
been explored so far. Observational and cross-sectional
human studies showed that in type 2 diabetes, osteocalcin
was associated with plasma glucose level and fat mass [4],
insulin sensitivity and secretion [5], glucose metabolism and
atherosclerosis parameters [6], and glycemic variability [7].
Consistent with animal studies, it was reported that a
circulating osteocalcin level was associated with improved
glucose tolerance, insulin secretion, and sensitivity [8]. In
addition, serum osteocalcin was closely associated with
lipid metabolism [9] and measures of adiposity [10].
Recently, human studies reported that low osteocalcin
levels were associated with metabolic syndrome [11–15],
independent from well-known metabolic syndrome risk
factors [12] and glucose metabolism [11], suggesting that
osteocalcin may be involved in the crosstalk between bone
and adipose tissue.
The aforementioned studies all describe significant
inverse associations of osteocalcin with type 2 diabetes,
insulin resistance, metabolic syndrome, measures of adi-
posity and lipid metabolism after adjustment for glucose and
lipid metabolism variables in multivariate analyses. How-
ever, although many previous studies focused on metabolic
syndrome in relation to bone metabolism [15, 16], they did
not clarify that the associations of circulating osteocalcin
with insulin resistance and energy metabolism exist inde-
pendently of bone mineral metabolism. The components of
metabolic syndrome were described as being associated with
decreased bone mineral density (BMD) [17]. The rate of
decline in BMD has been reported to be faster at the hip and
slower at the lumbar spine in women with diabetes mellitus
across menopause [18], and in comparison to controls,
postmenopausal women with type 2 diabetes mellitus had
lower levels of bone formation markers [19].
A few studies focused on postmenopausal women
regarding osteocalcin in relation to type 2 diabetes mellitus
[6, 20], glucose metabolism [9], and metabolic syndrome
[11].
In the present population-based study, we investigated
whether serum osteocalcin was associated with the com-
ponents of metabolic syndrome and type 2 diabetes mel-
litus in postmenopausal women. In this integrative study,
bone metabolism was also considered concurrently with
markers of energy and lipid metabolism.
Materials and methods
Community sampling
The study design was described in a previous study [21]. In
brief, 382 postmenopausal women who participated in the
extension part of the Iranian Multicentral Osteoporosis
Study were examined from 4 April to 22 September 2006.
The mean age (mean ± SD) of the women was
58.78 ± 7.8 years (range 50–83 years). They were ran-
domly selected from 13 clusters in Bushehr Port (the center
of Bushehr province, which has the longest border with the
Persian Gulf). All were community dwelling and ambula-
tory. The following exclusion criteria were used: (1) the
known presence of generalized bone diseases including
hyperparathyroidism, hypoparathyroidism, thyroid disor-
ders, rheumatoid arthritis, Cushing disease, and steroid-
induced osteoporosis; renal osteodystrophy; or other met-
abolic diseases; (2) a history of malignant diseases and
liver diseases; (3) drug addiction; and (4) restriction to bed
rest within the last 2 weeks after an illness or complete bed
rest for 3 months.
Physical examinations
A standard mercury sphygmomanometer was used to
measure blood pressure twice at the right arm after a
15-min rest in the sitting position. A stadiometer was used
to measure height and weight. Heavy outer garments and
shoes were removed before the participants’ height and
weight were measured. Body mass index (BMI) was cal-
culated. Waist circumference was defined at the midway
level between the costal margins and the iliac crests. Hip
circumference was measured at the level of the greater
trochanters.
BMD was determined at the lumbar spine (L2–L4) and
proximal femur (neck) using dual-energy X-ray absorpti-
ometry on an Osteocore II bone densitometer (Osteocore II
Osteodensitometer; Medilink, France). To eliminate oper-
ator discrepancies, the same operator tested all the women
during the study. Duplicate measurements were obtained
from 30 women who agreed to undergo a repeat assessment
on the same day, and the precision errors were calculated
using the root mean square method. The coefficients of
variation (CVs; precision) of measurements of the lumbar
spine and femoral neck were 0.8 and 1.6 %, respectively.
Laboratory measurements
A fasting blood sample was taken. All samples were
promptly centrifuged and separated, and the analyses were
carried out at the Persian Gulf Health Research Center on
the day of blood collection using a Selectra 2 autoanalyzer
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(Vital Scientific, Spankeren, The Netherlands). Glucose
was assayed by the enzymatic (glucose oxidase) colori-
metric method using a commercial kit (Pars Azmun, Teh-
ran, Iran). Serum TC and HDL-C were measured using a
cholesterol oxidase phenol aminoantipyrine method, and
TG was measured using a glycerol-3 phosphate oxidase
phenol aminoantipyrine enzymatic method. Serum LDL-C
was calculated using the Friedewald formula. LDL-C was
not calculated when the TG concentration was greater than
400 mg/dl.
The measurement of C-reactive protein (CRP) by a
high-sensitivity (hs) CRP assay and CRP HS enzyme-
linked immunosorbent assay (ELISA) (DRG International)
was conducted. The minimum detectable concentration of
the CRP HS ELISA assay was estimated to be 0.1 mg/l. In
addition, the functional sensitivity was determined to be
0.1 mg/l (as determined with interassay coefficient of
variation \20 %).
Serum osteoprotegerin (OPG) levels were measured
using an ELISA commercial kit (Biomedica Gruppe,
Vienna, Austria). The detection limit of the assay was
0.14 pmol/l. The mean intra- and interassay CVs of the
OPG assay were 4–10 and 7–8 %, respectively.
The receptor activator of nuclear factor-jB ligand
(RANKL) levels were measured using an ELISA with an
additional enhancement system (ampli-sRANKL; Bio-
medica Gruppe). The detection limit of the assay was
0.4 pg/ml. The mean intra- and interassay CVs of the
RANKL assay were 8–9 and 6–3 %, respectively.
The N-MID Osteocalcin ELISA (Nordic Bioscience
Diagnostics A/S) was used for the quantitative measure-
ment of osteocalcin in sera. The intra-assay CVs for the
low (7.0 ng/ml), medium (21.8 ng/ml), and high (43.2 ng/
ml) values were 3.4, 2.0, and 2.4 %, respectively.
The serum CrossLaps ELISA (Nordic Bioscience Diag-
nostics A/S, Herlev, Denmark) was used for the quantifi-
cation of degradation products of C-terminal telopeptides of
type I collagen in sera. The intra-assay CVs for low
(0.242 ng/ml), medium (0.375 ng/ml), and high (0.476 ng/
ml) values were 5.4, 5.0, and 5.1 %, respectively.
Serum alkaline phosphatase was determined by spec-
trophotometry using p-nitrophenylphosphate as substrate
(Pars Azmun, Tehran, Iran). Intra- and interassay CVs were
1.5 and 2.6 %, respectively.
Definitions
In accordance with the American Diabetes Association
criteria, diabetes was defined as either a fasting plasma
glucose of at least 126 mg/dl or use of antidiabetic mea-
sures [22].
The cutoff points of serum total cholesterol (TC), high
density lipoprotein cholesterol (HDL-C), and low-density
lipoprotein cholesterol (LDL-C), and serum triglycerides
(TG) distributions used to assign subjects to different levels
of risk were those derived from the National Cholesterol
Education Program (NCEP) guidelines in the USA [Adult
Treatment Panel (ATP) III, September 2002] [23]. A sub-
ject was considered hypertensive if blood pressure was at
least 140/90 mmHg or centrally obese if the waist-to-hip
ratio was at least 0.9.
Metabolic syndrome was diagnosed using the criteria
indicated by the NCEP-ATP III [23]. According to these
criteria, subjects with metabolic syndrome have any com-
bination of three or more of the following risk determi-
nants: fasting plasma glucose of at least 110 mg/dl, blood
pressure of at least 130/85 mmHg or antihypertensive
treatment, plasma TG of at least 150 mg/dl, HDL-C less
than 50 mg/dl, and waist circumference of at least 88 cm in
women.
Statistical analysis
The distribution of variables was studied using probability
plots and the Shapiro–Wilk test. We found that log trans-
formation of osteocalcin, hs-CRP, OPG, RANKL, and
CrossLaps gave a better fit to a Gaussian distribution. The
geometric mean for those biochemical variables was
defined as the arithmetic mean of the log-transformed data
± SD, raised to the power of 10.
A two-tailed t test was used to compare the mean values
across groups. Pearson correlation analysis was employed
to study the relationships between bone turnover markers
and the anthropometric, BMD, and biochemical variables.
For variables without normal distribution, log-transformed
data were used.
Binary logistic regression analysis was used to ascertain
the associations between low serum bone turnover markers
levels (below the median) and type 2 diabetes mellitus or
metabolic syndrome. In the full model, a low serum oste-
ocalcin level versus a high level (below or equal to the
median) was the independent variable of interest. Age, hs-
CRP, OPG, cardiovascular risk factors (according to
NCEP-ATP III criteria), CrossLaps, alkaline phosphatase,
BMD at femoral neck, and lumbar spine BMD were con-
sidered as covariates.
A p value less than 0.05 was accepted as the value of
significance. All statistical analyses were performed using
the PASW Statistics GradPack 18 (SPSS Inc., Chicago, IL,
USA).
Results
Subjects were stratified into low (below or equal to the
median) and high (above the median) serum osteocalcin
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groups. Serum osteocalcin had a median level of 9.82 ng/ml
for the total population (n = 382). The characteristics of
the study participants according to their serum osteocalcin
levels (osteocalcin below or osteocalcin above median) are
shown in Table 1.
There were no differences between the two groups with
regard to systolic and diastolic blood pressures, TC, LDL-
cholesterol, HDL-cholesterol, and RANKL levels. How-
ever, women with low osteocalcin levels (below median)
were younger, had higher serum hs-CRP, fasting glucose,
and TG levels, in addition to higher BMI, waist circum-
ference, measures of truncal obesity, and BMD at the
femoral neck and lumbar spine. They had lower CrossLaps
and alkaline phosphatase levels (Table 1).
Serum osteocalcin showed correlations with age
(r = 0.25, p \ 0.0001), waist-to-hip ratio (r = -0.10,
p = 0.036), BMI (r = -0.20, p \ 0.0001), BMD at the
femoral neck (r = -0.19, p \ 0.0001) and lumbar spine
(r = -0.26, p \ 0.0001), hs-CRP (r = -0.20, p \0.0001),
fasting glucose (r = -0.25, p \ 0.0001), TC (r = -0.12,
p = 0.017), TG (r = -0.15, p = 0.002), CrossLaps
(r = 0.49, p \ 0.0001), and alkaline phosphatase (r = 0.29,
p \ 0.0001) levels in bivariate analyses (Table 2). However,
serum osteocalcin levels had no significant correlations with
systolic and diastolic blood pressures, TC, LDL-cholesterol,
HDL-cholesterol, and OPG (p [ 0.05).
Serum CrossLaps showed correlations with age, waist
circumference, BMI, fasting glucose, TC, hs-CRP,
RANKL, osteocalcin, alkaline phosphatase, and BMD at
the femoral neck and lumbar spine (p \ 0.05, Table 2).
Serum alkaline phosphatase showed correlations with
fasting glucose, TC, LDL-cholesterol, osteocalcin, Cross-
Laps, and BMD at the lumbar spine (p \ 0.05, Table 2).
Of the studied population, 102 subjects (26.7 %) had
type 2 diabetes mellitus, and 261 women (68.32 %) met the
metabolic syndrome criteria (NCEP-ATP III criteria).
Table 3 shows a comparison of cardiovascular risk
factors, age, OPG, RANKL, hs-CRP, BMD and bone
turnover markers in patients with type 2 diabetes mellitus
and normal postmenopausal women. The serum osteocal-
cin level was lower in those with type 2 diabetes mellitus
[median 8.54 ng/ml, interquartile range (7.69–9.94 ng/ml)]
than those without diabetes [10.50 (8.55–13.67) ng/ml]
(p \ 0.0001). The patients with type 2 diabetes mellitus
had lower serum CrossLaps levels (p \ 0.0001). However,
they had higher levels of serum alkaline phosphatase
(p = 0.020, Table 3).
Age-adjusted lower osteocalcin levels (lower than
median) were associated with a higher odds ratio (OR) of
having type 2 diabetes mellitus (OR 4.29, CI [2.55–7.22],
p \ 0.0001) (Table 4). This association remained unchan-
ged after adjusting for further variables, including
Table 1 Characteristics of 382 postmenopausal women, stratified by serum osteocalcin below/equal or above median
All Serum osteocalcin B median Serum osteocalcin [ median p
Age (years) 58.71 ± 7.50 57.41 ± 6.53 60.02 ± 8.59 0.001
Waist circumference (cm) 99.12 ± 10.62 101.55 ± 9.95 97.19 ± 10.67 \0.0001
Body mass index (kg/m2) 28.34 ± 4.73 29.07 ± 4.99 27.55 ± 4.67 0.003
Waist-to-hip ratio 0.92 ± 0.06 0.93 ± 0.06 0.91 ± 0.06 0.019
Systolic blood pressure (mmHg) 126.19 ± 19.64 125.10 ± 19.87 126.95 ± 19.64 0.365
Diastolic blood pressure (mmHg) 78.80 ± 10.67 78.55 ± 10.30 78.97 ± 11.08 0.707
Fasting glucose (mg/dl) 115.71 ± 52.63 129.59 ± 65.68 102.75 ± 30.92 \0.0001
Total cholesterol (mg/dl) 235.02 ± 47.89 238.47 ± 47.89 232.24 ± 46.71 0.203
LDL-cholesterol (mg/dl) 157.35 ± 43.20 158.22 ± 43.29 156.91 ± 42.68 0.768
HDL-cholesterol (mg/dl) 40.98 ± 10.57 41.04 ± 11.25 41.01 ± 9.92 0.977
Triglyceride (mg/dl) 183.52 ± 96.26 196.09 ± 107.13 171.106 ± 82.53 0.014
Log(hs-CRP) (mg/l)a 1.89 ± 2.84 2.33 ± 2.93 1.55 ± 2.68 \0.0001
Osteoprotegerin (pg/ml)a 3.62 ± 1.55 3.58 ± 1.55 3.62 ± 1.56 0.792
RANKL (pg/ml)a 1.59 ± 3.00 1.43 ± 2.94 1.74 ± 2.97 0.085
Osteocalcin (ng/ml)a 11.45 ± 1.85 8.18 ± 1.1.10 14.09 ± 1.41 \0.0001
CrossLaps (ng/ml)a 0.58 ± 1.68 0.45 ± 1.57 0.73 ± 1.42 \0.0001
Alkaline phosphatase (U/l) 245.36 ± 90.21 223.08 ± 66.64 259.75 ± 91.12 \0.0001
Femoral neck BMD (g/cm2) 0.844 ± 0.184 0.881 ± 0.208 0.816 ± 0.162 0.001
Lumbar BMD (g/cm2) 0.946 ± 0.186 1.001 ± 0.189 0.902 ± 0.164 \0.0001
Data are given as mean ± SD unless otherwise indicated
BMD bone mineral density, hs-CRP high-sensitivity C-reactive protein, RANKL receptor activator of nuclear factor-jB ligand
a Geometric mean ± SD
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cardiovascular risk factors, hs-CRP, OPG, RANKL,
CrossLaps, alkaline phosphatase, and BMD at the femoral
neck and lumbar spine [OR 5.17, CI (2.66–10.04),
p \ 0.0001] (Table 4).
In multiple logistic regression analysis, lower CrossLaps
levels were associated with a higher OR of having type 2
diabetes mellitus when adjustments were made for age, hs-
CRP, cardiovascular risk factors, BMD, and markers of
bone metabolism [OR 2.51, CI (1.37–4.61), p = 0.003].
However, lower alkaline phosphatase levels were associ-
ated with a lower OR of having type 2 diabetes mellitus
[OR 0.28, CI (0.15–0.52), p \ 0.0001] in regression anal-
ysis (Table 4).
No significant difference was found between serum
osteocalcin, CrossLaps, alkaline phosphatase levels of
those with metabolic syndrome and those without meta-
bolic syndrome in different models using multiple logistic
regression analysis. Of the metabolic syndrome compo-
nents, low osteocalcin levels had significant associations
with elevated blood glucose [OR 1.89, CI (1.16–3.07),
p = 0.010] and elevated waist circumference [OR 2.53, CI
(1.13–5.67), p = 0.024] after adjustments for age, hs-CRP,
cardiovascular risk factors, BMD, and markers of bone
metabolism (Fig. 1).
Serum osteocalcin levels did not differ significantly
between subjects with and without hypertension and dysl-
ipidemia, according to the NCEP-ATP III criteria.
Discussion
We found that serum osteocalcin levels were independently
associated with glucose intolerance and abdominal obesity,
which are components of metabolic syndrome, and type 2
diabetes mellitus in postmenopausal women.
Several human studies were conducted in patients with
type 2 diabetes mellitus to assess the reciprocal relationship
between circulating osteocalcin and glucose metabolism
[4–6, 20, 24, 25].
In agreement with the results of our study, a significant
reduction in osteocalcin levels among type 2 diabetes mel-
litus patients compared with the normal glucose and
impaired fasting glucose groups was reported for the first
time in postmenopausal Korean women [20]. However, in
contrast to the Korean study for which the participants were
recruited from a periodic health checkup in a health pro-
motion center of a hospital [20], the current study was con-
ducted with a relatively large number of well-characterized
Table 2 Bivariate correlation analysis between bone turnover markers and cardiovascular risk factors, age, osteoprotegerin, RANKL, hs-CRP,
and BMD in postmenopausal women
Log(osteocalcin) Log(CrossLaps) Alkaline phosphatase
r p value r p value r p value
Age 0.25 \0.0001 -0.14 0.004 0.09 0.056
Waist circumference -0.22 \0.0001 -0.19 \0.0001 -0.05 0.247
Body mass index -0.20 \0.0001 -0.16 0.001 -0.05 0.308
Waist-to-hip ratio -0.10 0.036 -0.10 0.053 -0.02 0.694
Systolic blood pressure 0.09 0.063 -0.01 0.730 0.05 0.315
Diastolic blood pressure 0.01 0.719 -0.05 0.305 0.01 0.830
Fasting glucose -0.25 \0.0001 -0.27 \0.0001 0.19 \0.0001
Total cholesterol -0.12 0.017 -0.11 0.025 0.11 0.028
LDL-cholesterol -0.05 0.291 -0.06 0.195 0.12 0.013
HDL-cholesterol -0.04 0.410 -0.08 0.109 -0.02 0.600
Triglyceride -0.15 0.002 -0.09 0.083 0.01 0.882
Log(hs-CRP) -0.20 \0.0001 -0.23 \0.0001 0.09 0.079
Log(osteoprotegerin) 0.04 0.402 0.01 0.721 0.05 0.258
Log(RANKL) 0.07 0.151 0.17 0.001 0.08 0.094
Log(osteocalcin) – – 0.49 \0.0001 0.29 \0.0001
Log(CrossLaps) 0.49 \0.0001 – – 0.11 0.024
Alkaline phosphatase 0.29 \0.0001 0.11 0.024 – –
Femoral neck BMD -0.19 \0.0001 -0.11 0.024 -0.09 0.062
Lumbar BMD -0.26 \0.0001 -0.22 \0.0001 -0.11 0.031
Correlation coefficients and p values were calculated using Pearson correlation analysis
BMD bone mineral density, hs-CRP high-sensitivity C-reactive protein, RANKL receptor activator of nuclear factor-jB ligand
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postmenopausal women who were selected in a population-
based setting.
Another main strength of our study is that bone
metabolism was included concurrently with energy and
lipid metabolism in the regression analyses. In all previous
studies [4–6, 20, 24–26], the researchers considered only
energy and/or lipid metabolism markers in their analyses to
show inverse association of osteocalcin and glucose
metabolism.
Because our data are cross-sectional, only limited
inferences can be made regarding temporality and causa-
tion. Thus, we cannot indicate that a reduced serum oste-
ocalcin level is not caused by hyperglycemia or other
unidentified mechanisms that operate in diabetes mellitus.
Indeed, in previous human studies, it has been shown that
levels of bone turnover markers are lower in patients with
diabetes [27–29]. Our findings are consistent with these
previous studies that bone turnover markers (osteocalcin
Table 3 Comparison of
cardiovascular risk factors, age,
osteoprotegerin, RANKL, hs-
CRP, BMD, and bone turnover
markers in patients with type 2
diabetes mellitus and normal
postmenopausal women
Data are given as mean ± SD
unless otherwise indicated
BMD bone mineral density, hs-
CRP high-sensitivity C-reactive
protein, RANKL receptor
activator of nuclear factor-jB
ligand
a Geometric mean ± SD
Normal Type 2 diabetes mellitus p value
Age (years) 58.47 ± 8.07 59.67 ± 7.01 0.185
Waist circumference (cm) 98.63 ± 10.52 100.48 ± 10.86 0.134
Body mass index (kg/m2) 28.01 ± 4.46 28.36 ± 5.11 0.532
Waist-to-hip ratio 0.92 ± 0.07 0.94 ± 0.05 0.010
Systolic blood pressure (mmHg) 125.61 ± 18.25 127.76 ± 22.99 0.345
Diastolic blood pressure (mmHg) 78.73 ± 10.57 78.97 ± 10.97 0.849
Fasting glucose (mg/dl) 93.50 ± 13.56 176.45 ± 69.49 \0.0001
Total cholesterol (mg/dl) 235.93 ± 47.84 232.54 ± 48.17 0.542
LDL-cholesterol (mg/dl) 159.09 ± 43.06 152.59 ± 45.44 0.194
HDL-cholesterol (mg/dl) 42.04 ± 10.71 38.08 ± 9.70 0.001
Triglyceride (mg/dl) 174.03 ± 93.75 209.48 ± 98.70 0.001
Log(hs-CRP) (mg/l)a 1.77 ± 2.75 2.18 ± 2.95 0.066
Osteoprotegerin (pg/ml)a 69.18 ± 1.54 79.43 ± 1.54 0.009
RANKL (pg/ml)a 1.58 ± 2.88 1.58 ± 3.09 0.964
Osteocalcin (ng/ml)a 11.22 ± 1.44 9.12 ± 1.31 \0.0001
CrossLaps (ng/ml)a 0.64 ± 1.62 0.47 ± 1.63 \0.0001
Alkaline phosphatase (U/l) 238.88 ± 84.93 263.10 ± 101.62 0.020
Femoral neck BMD (g/cm2) 0.851 ± 0.183 0.838 ± 0.209 0.568
Lumbar BMD (g/cm2) 0.945 ± 0.189 0.961 ± 0.173 0.452
Table 4 Odds ratio and 95 % CI relating diabetes mellitus or metabolic syndrome as dependent variable, and bone turnover markers including
osteocalcin, cardiovascular risk factors, age, osteoprotegerin, RANKL, hs-CRP, and BMD as independent parameters in postmenopausal women
Type 2 diabetes mellitus Metabolic syndrome
OR CI p OR CI p
Osteocalcin
Unadjusted 3.71 2.26–6.11 \0.0001 1.37 0.87–2.14 0.164
Age-adjusted 4.29 2.55–7.22 \0.0001 1.48 0.94–2.33 0.089
Full modela 5.17 2.66–10.04 \0.0001 1.41 0.74–2.69 0.295
CrossLaps
Unadjusted 3.46 2.11–5.66 \0.0001 1.13 0.72–1.75 0.581
Age-adjusted 3.78 2.28–6.28 \0.0001 1.02 0.99–1.05 0.099
Full modela 2.51 1.37–4.61 0.003 1.24 0.67–2.28 0.479
Alkaline phosphatase
Unadjusted 0.60 0.38–0.95 0.030 0.63 0.41–0.99 0.047
Age-adjusted 0.61 0.38–0.96 0.036 1.02 0.99–1.05 0.123
Full modela 0.28 0.15–0.52 \0.0001 0.62 0.34–1.11 0.109
a Full model included bone turnover markers (lower than median), cardiovascular risk factors [low HDL-cholesterol (\40 mg/dl), high
LDL-cholesterol (C160 mg/dl), hypertension (C140/90 mmHg), waist-to-hip ratio (C0.9), smoking], log(hs-CRP), log(osteoprotegerin),
log(RANKL), and BMD at the femoral neck and lumbar area
J Bone Miner Metab
123
and CrossLaps) were suppressed by hyperglycemia in
patients with diabetes.
The status of bone resorption in hyperglycemia and
diabetes has not been well characterized and the results of
previous studies are conflicting [4, 20, 30, 31]. In contrast
to previous studies [4, 20, 30, 31], we found lower levels of
CrossLaps and higher alkaline phosphatase levels in
patients with diabetes. This discrepancy in levels of oste-
ocalcin, a marker for mature osteoblasts, and bone alkaline
phosphatase, a marker for immature osteoblasts, in diabetic
patients could be explained by the results of in vitro studies
that showed chronic hyperglycemia increases the activity
and expression of alkaline phosphatase, but decreases
osteocalcin expression [6, 32]. In fact, osteocalcin was
elevated and bone alkaline phosphatase was reduced after
treatment of diabetes [33, 34].
Recently, lower bone turnover was suggested as a
skeletal parameter that is present in type 2 diabetes mellitus
[19]. The results of our regression analyses revealed that
osteocalcin, CrossLaps, and alkaline phosphatase levels
were independently associated with type 2 diabetes melli-
tus. Thus, the unique contribution of osteocalcin as a bone
turnover marker in glucose metabolism could not be con-
cluded in the current study and the observed association
between osteocalcin and type 2 diabetes may simply reflect
the effects of diabetes and hyperglycemia on bone
metabolism.
To our knowledge, five clinical studies examined the
association between osteocalcin and metabolic syndrome
[11–15]. Of these studies, three examined the relationship
of circulating osteocalcin and metabolic syndrome in men.
Yeap et al. [15] reported a lower osteocalcin level in older
men with metabolic syndrome. An inverse relationship
between osteocalcin levels and the presence of metabolic
syndrome was reported among Chinese men [12, 14].
Osteocalcin levels in the highest quartile were associated
with a lower OR of having metabolic syndrome in blacks
and non-Hispanic whites [13]. The participants in this
cohort were old and predominantly hypertensive [13].
In contrast to the results of a Korean study that found the
ORs for metabolic syndrome were significantly higher in
the lowest quartile than in the highest quartile among
postmenopausal women [11], we did not find a significant
difference between osteocalcin levels of postmenopausal
women with metabolic syndrome and those without met-
abolic syndrome. The discrepancies between our obtained
results in postmenopausal women with the Korean study
cannot be explained until the results of more studies are
available. However, differences in the selection and the
characteristics of the studied populations, including race/
ethnicity, may be potential contributing factors.
Of the metabolic syndrome components, elevated blood
glucose and elevated waist circumference had a significant
association with lower osteocalcin levels when adjustments
were made for age, hs-CRP, cardiovascular risk factors,
BMD, and markers of bone metabolism in regression
models.
Our finding that abdominal obesity was inversely asso-
ciated with serum osteocalcin is in line with other animal
[35] and human studies [12, 14, 15]. Lee et al. [35] reported
that osteocalcin-deficient mice were obese. Osteocalcin
was a strong negative predictor of fat mass and trunk fat in
elderly Swedish men [25]. Im et al. [20] showed that serum
osteocalcin levels had a significant negative correlation
with BMI among postmenopausal women. In another
study, lower serum osteocalcin concentrations were
reported in obese postmenopausal women in comparison
with non-obese women [36]. Although obesity is associ-
ated with low bone turnover [26, 37], the relationship
between serum osteocalcin and adiposity needs a full
explanation.
We acknowledge that our study has several limitations.
In the present study, we used the NCEP-ATP III definition
of metabolic syndrome. Although this definition is the most
often used, other definitions of metabolic syndrome do
exist. Another limitation of our study includes the lack of
measurement of insulin resistance from fasting glucose and
insulin concentrations using the HOMA method. Although
we considered the participants’ lifestyle risk factors for
osteoporosis and cardiovascular diseases, a limitation is
that subjects who underwent insulin or sulfonylurea treat-
ments were not excluded.
In the current study, total serum osteocalcin was mea-
sured. Thus, the differential effects of carboxylated and
uncarboxylated forms of osteocalcin on glucose metabo-
lism and metabolic syndrome could not be examined.
Fig. 1 Odds ratio and 95 % CI relating the metabolic syndrome
components (as dependent variable), and osteocalcin (lower than
median) after adjustments for age, hs-CRP, cardiovascular risk
factors, bone mineral density, and markers of bone metabolism in
postmenopausal women
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Although animal and in vitro studies showed that the un-
carboxylated form appeared to mediate the effects of
osteocalcin in the regulation of glucose and energy
metabolism [35, 38], other in vitro and clinical studies
reported the importance of both types of osteocalcin in
glucose metabolism [4, 39]. Kanazawa et al. [4] reported
that both carboxylated and uncarboxylated forms of oste-
ocalcin were associated with blood glucose level in type 2
diabetes. Vitamin K is a cofactor for gamma-carboxylation
of osteocalcin (OC). This vitamin reduces circulating
osteocalcin while increasing calcification of the bone [2].
In fact, phylloquinone (K1) and menaquinone 7 (MK-7)
correlated inversely with uncarboxylated OC [40] and a
negative correlation between undercarboxylated OC and
MK-7 was reported in elderly women with type II diabetes
mellitus [41]. Furthermore, vitamin K supplementation for
36 months reduced progression of insulin resistance in
older men [42]. These findings demonstrate that vitamin K
status should be included in crosstalk between bone and
energy metabolism.
Since we assessed the investigated osteocalcin with
single measurements, the changes in osteocalcin levels
over time could not be reflected in the current study.
Another limitation of our study includes the lack of mea-
surement of other bone formation markers such as amino-
terminal procollagen type I propeptide (PINP).
In conclusion, serum osteocalcin was independently
associated with glucose intolerance and abdominal obesity,
which are components of metabolic syndrome, and type 2
diabetes mellitus in postmenopausal women. These findings
may suggest the independent role of osteocalcin in the
crosstalk between bone and energy metabolism in humans.
However, we also observed that low CrossLaps and high
alkaline phosphatase levels were independently associated
with type 2 diabetes mellitus. Therefore, the unique contri-
bution of osteocalcin as a bone turnover marker in type 2
diabetes mellitus could not be concluded in the current study.
In a recent study, daily injections of osteocalcin signif-
icantly affected glucose handling in wild-type mice,
improved insulin sensitivity, prevented obesity, and pro-
tected against liver steatosis [43]. Therefore, on the basis of
the results of this animal study, further research is required
to evaluate whether interventions that raise osteocalcin
levels might contribute to the development of treatments
for components of metabolic syndrome such as obesity and
diabetes mellitus in humans.
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